tecovirimat (TPOXX, ST-246)
Jump to navigation
Jump to search
Indications
- treatment of smallpox*
- available via an expanded access Investigational New Drug (IND) protocol for treatment of monkeypox[3]
* advanced as a therapy for smallpox in accordance with the FDA Animal Rule. (FDA-approved July 2018)[2]
Dosage
injectable for intravenous administration[3]
oral capsule
- optimal drug absorption of the oral formulation requires concurrent intake of a high-fat meal (ideally ~600 calories & 25 g of fat)[3]
Comparative biology
- 10 mg/kg for 14 days in monkeypox model
More general terms
References
- ↑ Grosenbach DW, Honeychurch K, Rose EA Oral Tecovirimat for the Treatment of Smallpox. N Engl J Med 2018; 379:44-53. July 5, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29972742 https://www.nejm.org/doi/full/10.1056/NEJMoa1705688
- ↑ 2.0 2.1 FDA News Release. July 13, 2018 FDA approves the first drug with an indication for treatment of smallpox. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613496.htm
- ↑ 3.0 3.1 3.2 3.3 del Rio C, Malani PN Update on the Monkeypox Outbreak. JAMA. Published online August 11, 2022. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35951336 https://jamanetwork.com/journals/jama/fullarticle/2795359